Aptevo Therapeutics is a biotech company developing immunotherapeutic treatments for cancer in the US. Their main focus is on developing APVO436, a bispecific antibody currently in Phase 1b clinical trials for treating leukemia and myelodysplastic syndrome. They also have other bispecific candidate treatments in preclinical stages, including ALG.APV-527 and APVO603 which target various forms of cancer.